The results were evaluated by the fatty liver index and the NAFLD liver fat score, with a significant reduction in patients treated with SGLT2, although this difference between the two groups was not demonstrated for CAP [87]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.